Sio Capital Management LLC Buys New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sio Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,349,274 shares of the company’s stock, valued at approximately $24,314,000. Teva Pharmaceutical Industries comprises 9.6% of Sio Capital Management LLC’s holdings, making the stock its 2nd biggest holding.

A number of other hedge funds have also modified their holdings of the business. Northwest & Ethical Investments L.P. lifted its stake in shares of Teva Pharmaceutical Industries by 108.3% during the third quarter. Northwest & Ethical Investments L.P. now owns 10,000 shares of the company’s stock valued at $180,000 after buying an additional 5,200 shares during the period. Vinva Investment Management Ltd boosted its stake in shares of Teva Pharmaceutical Industries by 964.6% during the 3rd quarter. Vinva Investment Management Ltd now owns 217,720 shares of the company’s stock valued at $3,801,000 after buying an additional 197,270 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Teva Pharmaceutical Industries by 237.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after acquiring an additional 2,376,668 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Teva Pharmaceutical Industries by 23.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 580,967 shares of the company’s stock valued at $10,469,000 after buying an additional 110,300 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Teva Pharmaceutical Industries by 3.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 453,251 shares of the company’s stock worth $8,168,000 after acquiring an additional 14,372 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 0.1 %

NYSE TEVA opened at $16.57 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company’s 50 day simple moving average is $17.57 and its 200 day simple moving average is $17.35.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.